1.401USD+6.98%Mkt Cap: 68.11M USDP/E: —Last update: 2026-05-26
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical t…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap68.11M USD
Enterprise Value-29.80M USD
Revenue (TTM)—
Gross Profit-26.59M USD
Net Income (TTM)-90.97M USD
Revenue/Share—
Last Price1.401 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG1.62
EV/EBITDA0.50
EV/Revenue—
P/S—
P/B0.84
EPS (TTM)-1.61
EPS (Forward)—
52W Range
1.1606% of range4.980
52W High4.980 USD
52W Low1.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-122.27%
ROA-76.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.25M USD
CapEx (TTM)581.00K USD
FCF Margin—
FCF Yield29.68%
Net Debt-95.50M USD
Net Debt/EBITDA1.61
Balance Sheet
Debt/Equity—
Current Ratio2.23
Quick Ratio2.18
Book Value/Sh1.540 USD
Cash/Share1.977 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 13, 2012
Pay Date—
Splits
Last Split1:7
Split DateMay 10, 2017
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)8.000 USD
Target Range8.000 USD – 8.000 USD
# Analysts1
Ownership
Shares Out.48.31M
Float45.05M
Insiders11.02%
Institutions29.03%
Short Interest
Short Ratio19.0d
Short % Float14.64%
Short % Out.14.34%
Shares Short6.93M
Short (prev mo.)7.32M
Technical
SMA 501.595 (-12.2%)
SMA 2002.383 (-41.2%)
Beta-0.76
S&P 52W Chg28.31%
Avg Vol (30d)425.01K
Avg Vol (10d)337.20K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—